Abemaciclib - Eli Lilly and Company
Alternative Names: Abemaciclib mesylate; Bemaciclib; Bemaciclib mesylate; LY 2835219; Verzenio; VerzeniosLatest Information Update: 01 Jul 2024
At a glance
- Originator Eli Lilly and Company
- Developer Boehringer Ingelheim; Dana-Farber Cancer Institute; Eli Lilly; Eli Lilly and Company; Jules Bordet Institute; M. D. Anderson Cancer Center; Memorial Sloan-Kettering Cancer Center; Merck Sharp & Dohme; UCLAs Jonsson Comprehensive Cancer Center; Washington University School of Medicine
- Class Aminopyridines; Antineoplastics; Benzimidazoles; Fluorinated hydrocarbons; Piperazines; Pyrimidines; Small molecules
- Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Breast cancer
- Phase III HER2 negative breast cancer; Liposarcoma; Prostate cancer
- Phase II Adenocarcinoma; Brain cancer; Cholangiocarcinoma; Endometrial cancer; Ewing's sarcoma; Fallopian tube cancer; Glioblastoma; Mantle-cell lymphoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Solid tumours; Urogenital cancer
- Phase I/II Head and neck cancer
- Phase I Myelofibrosis
- No development reported Cancer; Renal cell carcinoma
Most Recent Events
- 27 Jun 2024 phase-I development in Breast-cancer(Combination therapy, Late-stage disease, Metastatic disease) is ongoing in Finland, Denmark (PO, Tablet) (NCT03099174)
- 27 Jun 2024 Phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease) is ongoing in Spain, Japan, France, Finland, Denmark, USA, (PO) (NCT03099174)
- 21 Jun 2024 Brown University terminates a phase I trial in Renal cell carcinoma (Combination therapy, Metastatic disease, Second-line therapy or greater, Late-stage disease) in USA (PO) due to withdraw of funding (NCT03905889)